Related Experiment Video

Updated: Jun 17, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Compounds in clinical Phase III and beyond

Torsten Kessler1, Michael Bayer, Christian Schwöppe

  • 1Department of Medicine, Hematology and Oncology, University of Münster, Albert-Schweitzer-Strasse, 33, 48129, Münster, Germany. torstenkessler@uni-muenster.de

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|December 25, 2009
PubMed

Insights

Targeted cancer therapies, including angiogenesis inhibitors, are revolutionizing treatment. Several drugs, like bevacizumab and tyrosine kinase inhibitors, are approved, with more in advanced clinical trials.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Targeted cancer therapies are increasingly vital in modern treatment strategies.
  • Inhibition of tumor angiogenesis and vascular targeting are key areas of research.
  • Numerous novel angiogenesis inhibitors have been developed and assessed in clinical trials.

Purpose of the Study:

  • To provide an overview of antiangiogenic substances currently under investigation in Phase III studies and beyond.
  • To highlight the progress and potential of vascular targeting agents in cancer therapy.

Main Methods:

  • Review of clinical trial data for angiogenesis inhibitors.
  • Analysis of approved antiangiogenic drugs and their indications.
  • Focus on agents progressing through Phase III and later stages of development.

Main Results:

  • Several angiogenesis inhibitors, including bevacizumab (a vascular endothelial growth factor neutralizing antibody), have been approved for various cancers.
  • Tyrosine kinase (TK) inhibitors such as sorafenib and sunitinib are approved for renal cancer, hepatocellular carcinoma, and gastrointestinal stroma tumors.
  • A significant number of new antiangiogenic agents are currently in advanced clinical trials.

Conclusions:

  • Antiangiogenesis therapy represents a promising frontier in cancer treatment.
  • Approved drugs demonstrate the clinical efficacy of targeting tumor vascularization.
  • Ongoing research and clinical trials are expected to yield further advancements in this field.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Phase II Reactions: Miscellaneous Conjugation Reactions01:19

Phase II Reactions: Miscellaneous Conjugation Reactions

Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...